Thromboangiitis Obliterans (Buerger's Disease)

Definition

Epidemiology

• Typically affects young adults, ages 20-50, with onset almost always before age 35-40
• Strongly male-predominant historically, though the sex gap has narrowed as female smoking rates rose
• Higher prevalence in Asia and the Middle East compared with North America (diagnosed in less than 1% of severe limb ischemia cases in the West, but up to 24% of young adults presenting with lower limb ischemia in some series)
• Essentially never occurs in non-smokers or non-tobacco users
• Robbins & Kumar Basic Pathology, p. 334
• Schwartz's Principles of Surgery, p. 1001-1002

Etiology

• Direct endothelial cell toxicity from a component of tobacco
• Endothelial dysfunction with reduced endothelium-dependent vasodilation and increased release of prothrombotic substances
• An immune-mediated hypersensitivity reaction - most patients show hypersensitivity to intradermal tobacco extracts, suggesting a cell-mediated immune response to a tobacco-modified vessel wall antigen
• Genetic susceptibility - associations with certain HLA haplotypes have been reported

Pathology (Morphology)

• Acute phase: mixed inflammatory infiltrate with luminal thrombosis; small microabscesses within the thrombus, sometimes rimmed by granulomatous inflammation, containing dense polymorphonuclear leukocyte aggregation and multinucleated giant cells
• Inflammation characteristically extends outward into the contiguous veins and nerves - a feature unusual in most other vasculitides, and this is why patients get painful superficial thrombophlebitis and neuritic pain
• Chronic phase: decreasing hypercellularity, with organization and recanalization of the thrombus
• End-stage: the artery and surrounding structures become encased in dense fibrous tissue
• Robbins & Kumar Basic Pathology, p. 334
• Schwartz's Principles of Surgery, p. 1001

Clinical Features

• Claudication: instep/foot, calf, hand, or arm claudication - often initially mistaken for a joint or neuromuscular problem
• Raynaud phenomenon: cold-induced digital pallor/cyanosis
• Migratory superficial thrombophlebitis: seen in up to 16% of patients, and an important clue to the systemic inflammatory nature of the disease
• Ischemic rest pain, often severe and disproportionate to objective findings, likely due to nerve involvement
• Digital ulceration and gangrene of toes and fingers as disease progresses
• Multiple limbs are usually involved, even if some are asymptomatic
• Buerger's postural (dependency-rubor) test may be positive on clinical exam (S Das, Manual on Clinical Surgery)

• Schwartz's Principles of Surgery, p. 1001-1002
• Bailey and Love's Short Practice of Surgery, p. 8615-8618

Diagnosis

• Age of onset under 45, current or recent heavy tobacco use
• Distal extremity ischemia (claudication, rest pain, ulcers, or gangrene) confirmed by non-invasive testing
• Exclusion of diabetes mellitus, hyperlipidemia, and autoimmune/connective tissue disease as causes
• Exclusion of a proximal embolic source
• Consistent arteriographic findings in the clinically involved and non-involved limbs

Treatment

• Absolute tobacco cessation is the only intervention proven to alter the natural history. In patients who fully abstain, disease remission is common and amputation risk drops substantially (limb loss roughly 35% in those who quit versus 67% in those who continue smoking, per Schwartz's Principles of Surgery). If lesions are already established, abstinence halts progression but does not reverse existing damage (Bailey and Love's Short Practice of Surgery).
• Surgical revascularization has a limited role - because the disease affects small distal vessels diffusely, there is often no acceptable distal target for bypass, and autogenous vein conduits are limited by coexisting migratory phlebitis.
• Pharmacologic therapy is largely ineffective; agents such as calcium channel blockers, iloprost (a prostacyclin analog), and endothelin receptor antagonists (bosentan) have shown modest symptomatic benefit in some small studies but are not disease-modifying.
• Endovascular angioplasty is increasingly used for focal occlusive segments, though data remain limited to small case series and meta-analyses of retrospective data.
• Sympathectomy may reduce vasospasm and improve rest pain/wound healing in select cases.
• Emerging options: therapeutic angiogenesis (growth factor or autologous bone marrow/stem cell therapy) has shown promising short-term results in small trials, but long-term data are lacking.
• Amputation may ultimately be required when ischemia is advanced and no other option remains.
• Schwartz's Principles of Surgery, p. 1002
• Bailey and Love's Short Practice of Surgery, p. 8617-8618

Recent Evidence (Literature Check)

• A 2025 systematic review and meta-analysis of treatment outcomes in Buerger disease compared endovascular procedures, sympathectomy, and stem cell therapy, reinforcing that no single intervention is curative and smoking cessation remains central (PMID: 39847853).
• A 2023 systematic review/meta-analysis specifically evaluated endovascular balloon angioplasty outcomes in TAO with chronic limb ischemia, reporting reasonable early patency but higher restenosis rates than in atherosclerotic disease given ongoing small-vessel inflammation (PMID: 36174815).
• A 2024 Mendelian randomization study explored circulating inflammatory protein signatures as potential causal contributors to TAO risk, an early step toward better understanding disease biology beyond tobacco exposure alone (PMID: 38788766).

Key Distinguishing Points vs. Other Vasculitides